

#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Wessels 1



| Section 1.                                                                                                     | Identifying Inform                                                                                                    | nation                                                                                           |                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |
|----------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------|
| 1. Given Name (Fi<br>Sabine                                                                                    | rst Name)                                                                                                             | 2. Surname (Last Name<br>Wessels                                                                 | )                                              | 3. Date<br>24-April-2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 020                    |
| 4. Are you the cor                                                                                             | responding author?                                                                                                    | ☐ Yes ✓ No                                                                                       | Correspondir<br>Marc A Schr                    | ng Author's Name<br>neider                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                        |
| 5. Manuscript Title<br>Comprehensive                                                                           |                                                                                                                       | vanced NSCLC: feasibili                                                                          | ty, challenges an                              | d perspectives                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                        |
| 6. Manuscript Ider<br>TLCR-20-137                                                                              | ntifying Number (if you kr                                                                                            | now it)                                                                                          |                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |
|                                                                                                                |                                                                                                                       |                                                                                                  |                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |
| Section 2.                                                                                                     | The Work Under Co                                                                                                     | onsideration for Pul                                                                             | olication                                      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |
| any aspect of the s<br>statistical analysis,<br>Are there any rel<br>If yes, please fill of<br>Excess rows can | ubmitted work (including<br>etc.)?<br>evant conflicts of intere<br>out the appropriate info<br>be removed by pressing | est? Yes Not limited to grants  Pest? Yes Not limited to grants  Pest? Yes Not limited to grants | , data monitoring b<br>o<br>nave more than c   | overnment, commercial, proportion of the proport | cript preparation,     |
| Name of Institut                                                                                               | ion/Company                                                                                                           | Grant? Personal Fees?                                                                            | Support?                                       | Other Comments                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |                        |
| German Center for Lu                                                                                           | ing Research (DZL)                                                                                                    | <b>✓</b>                                                                                         |                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |
|                                                                                                                | ı                                                                                                                     |                                                                                                  |                                                |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |
| Section 3.                                                                                                     | Relevant financial                                                                                                    | activities outside th                                                                            | e submitted w                                  | ork.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                        |
| of compensation<br>clicking the "Add<br>Are there any rel                                                      | ) with entities as descri<br>  +" box. You should rep<br>evant conflicts of intere                                    | ibed in the instructions<br>port relationships that v<br>est? Yes 🗸 No                           | . Use one line for<br>were <b>present du</b> i | e financial relationships<br>each entity; add as man<br>ring the 36 months pric                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | y lines as you need by |
| Section 4.                                                                                                     | Intellectual Proper                                                                                                   | rty Patents & Copy                                                                               | rights                                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                        |
| Do you have any                                                                                                | patents, whether plan                                                                                                 | ned, pending or issued                                                                           | , broadly relevant                             | t to the work? Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | ✓ No                   |

Wessels 2



| Section 5. Polationships not sovered above                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Relationships not covered above                                                                                                                                                                                                      |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |
| Disclosure Statement                                                                                                                                                                                                                 |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |
| Dr. Wessels reports grants and personal fees from German Center for Lung Research (DZL), during the conduct of the study; .                                                                                                          |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Wessels 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

### Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

patent

Muley 1



| Section 1. Identifying Inform                                                                                             | ation                                                                       |                                                                                                                                            |                    |  |  |
|---------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|--------------------|--|--|
| Given Name (First Name) Thomas                                                                                            | 2. Surname (Last Name)<br>Muley                                             | 3. Date<br>24-April-2020                                                                                                                   | 0                  |  |  |
| 4. Are you the corresponding author?                                                                                      | Yes ✓ No                                                                    | Corresponding Author's Name<br>Marc A. Schneider                                                                                           |                    |  |  |
| 5. Manuscript Title<br>Comprehensive serial biobanking in adv                                                             | vanced NSCLC: feasibility,                                                  | challenges and perspectives                                                                                                                |                    |  |  |
| 6. Manuscript Identifying Number (if you kn<br>TLCR-20-137                                                                | ow it)                                                                      |                                                                                                                                            |                    |  |  |
|                                                                                                                           |                                                                             |                                                                                                                                            |                    |  |  |
| Section 2. The Work Under Co                                                                                              | onsideration for Public                                                     | cation                                                                                                                                     |                    |  |  |
| any aspect of the submitted work (including<br>statistical analysis, etc.)?<br>Are there any relevant conflicts of intere | but not limited to grants, danst.  St? Yes No  Symmation below. If you have | a third party (government, commercial, priva<br>ita monitoring board, study design, manuscrip<br>we more than one entity press the "ADD" b | ot preparation,    |  |  |
| Name of Institution/Company  Grant? Personal Non-Financial Support? Comments                                              |                                                                             |                                                                                                                                            |                    |  |  |
| BMBF, German Center for Lung Research (DZL)                                                                               | <b>✓</b>                                                                    |                                                                                                                                            |                    |  |  |
|                                                                                                                           |                                                                             |                                                                                                                                            |                    |  |  |
| Section 3. Relevant financial a                                                                                           | activities outside the s                                                    | submitted work.                                                                                                                            |                    |  |  |
| of compensation) with entities as descri                                                                                  | bed in the instructions. Use port relationships that were st?               | ether you have financial relationships (register) one line for each entity; add as many ling the 36 months prior t                         | nes as you need by |  |  |
| Name of Entity                                                                                                            | Grant                                                                       | n-Financial other? Comments                                                                                                                |                    |  |  |
| Roche                                                                                                                     | <b>✓</b>                                                                    |                                                                                                                                            |                    |  |  |

Muley 2



| Section 4. Intellectual Property Patents & Copyrights                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo                                                                                                                                     |
| Section 5. Relationships not covered above                                                                                                                                                                                            |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                             |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                                |
| No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                         |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                       |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                     |
| Dr. Muley reports grants and personal fees from BMBF, German Center for Lung Research (DZL), during the conduct of the study; grants and personal fees from Roche, outside the submitted work; .                                      |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Muley 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not **Royalties:** Funds are coming in to you or your institution due to your

**Royalties:** Funds are coming in to you or your institution due to your patent

Christopoulos 1



| Section 1. Ide                                                                                                                       | ntifying Inform                                                   | nation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                          |                                          |                                  |                       |                   |       |
|--------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------|------------------------------------------|----------------------------------|-----------------------|-------------------|-------|
| Given Name (First Nar<br>Petros                                                                                                      |                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | me (Last Name                            | )                                        |                                  | 3. Date<br>12-April-2 | 2020              |       |
| 4. Are you the correspor                                                                                                             | nding author?                                                     | Yes                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | <b>√</b> No                              | Correspond<br>Marc Schr                  | -                                | r's Name              |                   |       |
| 5. Manuscript Title<br>Comprehensive serial                                                                                          | biobanking in ad                                                  | vanced NS                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | SCLC: feasibili                          | ty, challenges a                         | and perspe                       | ectives               |                   |       |
| 6. Manuscript Identifyin                                                                                                             | g Number (if you kr                                               | now it)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                          |                                          |                                  |                       |                   |       |
|                                                                                                                                      |                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |                                          |                                          |                                  |                       |                   |       |
| Section 2. The                                                                                                                       | Work Under Co                                                     | onsidera                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | tion for Puk                             | olication                                |                                  |                       |                   |       |
| Did you or your institution any aspect of the submit statistical analysis, etc.)?  Are there any relevant                            | ted work (including                                               | but not lin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |                                          | data monitoring                          |                                  |                       |                   |       |
| Section 3. Rele                                                                                                                      | evant financial                                                   | activitie                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | s outside th                             | e submitted                              | work.                            |                       |                   |       |
| Place a check in the ap<br>of compensation) with<br>clicking the "Add +" bo<br>Are there any relevant<br>If yes, please fill out the | n entities as descri<br>ox. You should rep<br>conflicts of intere | bed in the port relations to the port of t | e instructions.<br>onships that v<br>Yes | Use one line fo<br>vere <b>present d</b> | or each en<br>l <b>uring the</b> | tity; add as man      | y lines as you ne | ed by |
| Name of Entity                                                                                                                       |                                                                   | Grant?                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Personal N                               | Ion-Financial Support?                   | Other?                           | Comments              |                   |       |
| Novartis                                                                                                                             |                                                                   | <b>✓</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | <b>✓</b>                                 |                                          |                                  |                       |                   |       |
| Roche                                                                                                                                |                                                                   | <b>√</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | <b>✓</b>                                 |                                          |                                  |                       |                   |       |
| AstraZeneca                                                                                                                          |                                                                   | <b>✓</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                          |                                          |                                  |                       |                   |       |
| Takeda                                                                                                                               |                                                                   | <b>✓</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                          |                                          |                                  |                       |                   |       |
| Chugai                                                                                                                               |                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <b>✓</b>                                 |                                          |                                  |                       |                   |       |
| Boehringer                                                                                                                           |                                                                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                | <b>✓</b>                                 |                                          |                                  |                       |                   |       |

Christopoulos 2



| Section 4. Intellectual Property Patents & Copyrights                                                                                                                                                                                       |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Vo                                                                                                                                           |
| Section 5. Relationships not covered above                                                                                                                                                                                                  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                                   |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                                      |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                             |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships.        |
| Section 6. Disclosure Statement                                                                                                                                                                                                             |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                           |
| Dr. Christopoulos reports grants and personal fees from Novartis, grants and personal fees from Roche, grants from AstraZeneca, grants from Takeda, personal fees from Chugai, personal fees from Boehringer, outside the submitted work; . |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Christopoulos 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Meister 1



| Section 1.                                                                                 | Identifying Inform                                              | ation                                           |                             |                                                                                                                            |
|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-------------------------------------------------|-----------------------------|----------------------------------------------------------------------------------------------------------------------------|
| 1. Given Name (Fi<br>Michael                                                               | rst Name)                                                       | 2. Surname (Last Name)<br>Meister               |                             | 3. Date<br>24-April-2020                                                                                                   |
| 4. Are you the corresponding author?                                                       |                                                                 | Yes ✓ No                                        | Corresponding Author's      | s Name                                                                                                                     |
| 5. Manuscript Title<br>Comprehensive                                                       |                                                                 | vanced NSCLC: feasibility                       | , challenges and perspec    | ctives                                                                                                                     |
| 6. Manuscript Ider<br>TLCR-20-137                                                          | ntifying Number (if you kn                                      | now it)                                         | _                           |                                                                                                                            |
|                                                                                            | I                                                               |                                                 |                             |                                                                                                                            |
| Section 2.                                                                                 | The Work Under Co                                               | onsideration for Publ                           | ication                     |                                                                                                                            |
| any aspect of the s<br>statistical analysis,<br>Are there any rel<br>If yes, please fill o | ubmitted work (including<br>etc.)?<br>evant conflicts of intere | est? Yes No<br>prmation below. If you ha        | lata monitoring board, stud | t, commercial, private foundation, etc.) for<br>dy design, manuscript preparation,<br>press the "ADD" button to add a row. |
| Name of Institut                                                                           | ion/Company                                                     | Grant? Personal No                              | on-Financial Other?         | Comments                                                                                                                   |
| German Center for Lu                                                                       | ıng Research                                                    | <b>✓</b>                                        |                             |                                                                                                                            |
|                                                                                            | ı                                                               |                                                 |                             |                                                                                                                            |
| Section 3.                                                                                 | Relevant financial                                              | activities outside the                          | submitted work.             |                                                                                                                            |
| of compensation<br>clicking the "Add<br>Are there any rel                                  | ) with entities as descri                                       | bed in the instructions. Uport relations his we | Ise one line for each enti  | al relationships (regardless of amount<br>ity; add as many lines as you need by<br><b>36 months prior to publication</b> . |
| Section 4.                                                                                 | Intellectual Proper                                             | ty Patents & Copyri                             | ights                       |                                                                                                                            |
| Do you have any                                                                            | patents, whether plani                                          | ned, pending or issued, b                       | roadly relevant to the w    | ork? ☐ Yes ✓ No                                                                                                            |

Meister 2



| Section 5.                   |                                                                                                                                                                                                     |
|------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section 5.                   | Relationships not covered above                                                                                                                                                                     |
|                              | ationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?                                                 |
| Yes, the followi             | ng relationships/conditions/circumstances are present (explain below):                                                                                                                              |
| ✓ No other relation          | onships/conditions/circumstances that present a potential conflict of interest                                                                                                                      |
|                              | uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>als may ask authors to disclose further information about reported relationships. |
|                              |                                                                                                                                                                                                     |
| Section 6.                   | Disclosure Statement                                                                                                                                                                                |
| Based on the above<br>below. | e disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                           |
| Dr. Meister reports          | grants from German Center for Lung Research, during the conduct of the study; .                                                                                                                     |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Meister 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

Heinzmann-Groth

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

1

administrative support, etc.



| Section 1. Identifying Inforn                                                                                                                                                                                                                                                                                                                                                                                                                       | nation                                    |                                               |  |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------|-----------------------------------------------|--|--|--|
| Given Name (First Name)     Ingrid Paula                                                                                                                                                                                                                                                                                                                                                                                                            | 2. Surname (Last Name)<br>Heinzmann-Groth | 3. Date<br>24-April-2020                      |  |  |  |
| 4. Are you the corresponding author?                                                                                                                                                                                                                                                                                                                                                                                                                | ☐ Yes 🗸 No                                | Corresponding Author's Name<br>Marc Schneider |  |  |  |
| 5. Manuscript Title<br>Comprehensive serial biobanking in ad                                                                                                                                                                                                                                                                                                                                                                                        | vanced NSCLC: feasibility,                | challenges and perspectives                   |  |  |  |
| 6. Manuscript Identifying Number (if you k                                                                                                                                                                                                                                                                                                                                                                                                          | now it)                                   |                                               |  |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                           |                                               |  |  |  |
| Section 2. The Work Under C                                                                                                                                                                                                                                                                                                                                                                                                                         | onsideration for Public                   | cation                                        |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?                                                                                                                               |                                           |                                               |  |  |  |
| Are there any relevant conflicts of interest? Yes V No                                                                                                                                                                                                                                                                                                                                                                                              |                                           |                                               |  |  |  |
| Section 3. Relevant financial                                                                                                                                                                                                                                                                                                                                                                                                                       | activities outside the                    | submitted work                                |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                                           |                                               |  |  |  |
| Section 4. Intellectual Prope                                                                                                                                                                                                                                                                                                                                                                                                                       | rty Patents & Copyric                     | nhts                                          |  |  |  |
| Intellectual Proper                                                                                                                                                                                                                                                                                                                                                                                                                                 |                                           |                                               |  |  |  |
| Do you have any patents, whether plan                                                                                                                                                                                                                                                                                                                                                                                                               | ined, pending or issued, br               | oadly relevant to the work? Yes V No          |  |  |  |

Heinzmann-Groth 2



| Section 5.                |                                                                                                                                                                                                     |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section 5.                | Relationships not covered above                                                                                                                                                                     |
|                           | itionships or activities that readers could perceive to have influenced, or that give the appearance of ing, what you wrote in the submitted work?                                                  |
| Yes, the following        | ng relationships/conditions/circumstances are present (explain below):                                                                                                                              |
| ✓ No other relatio        | onships/conditions/circumstances that present a potential conflict of interest                                                                                                                      |
|                           | uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>als may ask authors to disclose further information about reported relationships. |
| Section 6.                | Pisclosure Statement                                                                                                                                                                                |
| Based on the above below. | e disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                           |
| Dr. Heinzmann-Gro         | oth has nothing to disclose.                                                                                                                                                                        |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Heinzmann-Groth 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

**Other:** Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Warth 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Identifying Inform         | nation                          |                                                                                                                                    |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|---------------------------------|------------------------------------------------------------------------------------------------------------------------------------|--|
| 1. Given Name (Fi<br>Arne                                                                                                                                                                                                                                                                                                                                                                                                                           | rst Name)                  | 2. Surname (Last Name)<br>Warth | 3. Date<br>24-April-2020                                                                                                           |  |
| 4. Are you the corresponding author?                                                                                                                                                                                                                                                                                                                                                                                                                |                            | Yes ✓ No                        | Corresponding Author's Name<br>Marc A. Schneider                                                                                   |  |
| 5. Manuscript Title<br>Comprehensive                                                                                                                                                                                                                                                                                                                                                                                                                |                            | vanced NSCLC: feasibility,      | challenges and perspectives                                                                                                        |  |
| 6. Manuscript Ide<br>TLCR-20-137                                                                                                                                                                                                                                                                                                                                                                                                                    | ntifying Number (if you kr | now it)                         |                                                                                                                                    |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            |                                 |                                                                                                                                    |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                          | The Work Under Co          | onsideration for Public         | cation                                                                                                                             |  |
| any aspect of the s<br>statistical analysis,                                                                                                                                                                                                                                                                                                                                                                                                        | ubmitted work (including   | but not limited to grants, da   | a third party (government, commercial, private foundation, etc.) for<br>ta monitoring board, study design, manuscript preparation, |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant financial         | activities outside the s        | submitted work.                                                                                                                    |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                            |                                 |                                                                                                                                    |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Intellectual Proper        | rty Patents & Copyric           | ıhts                                                                                                                               |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                     | patents, whether plan      | ned, pending or issued, br      | oadly relevant to the work? Yes V No                                                                                               |  |

Warth 2



| Section 5.       |                                                                                                                                                                                                         |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Deculon 5.       | Relationships not covered above                                                                                                                                                                         |
|                  | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?                                                 |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):                                                                                                                                |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest                                                                                                                        |
|                  | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.       | Disclosure Statement                                                                                                                                                                                    |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                             |
| Dr. Warth has no | othing to disclose.                                                                                                                                                                                     |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Warth 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Herpel 1



| Section 1. Identifying Infor                                                                                                                                                                                                                                                                                                                                                                                                                        | mation                           |                                                |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------|------------------------------------------------|--|--|
| 1. Given Name (First Name)<br>Esther                                                                                                                                                                                                                                                                                                                                                                                                                | 2. Surname (Last Name)<br>Herpel | 3. Date<br>24-April-2020                       |  |  |
| 4. Are you the corresponding author?                                                                                                                                                                                                                                                                                                                                                                                                                | Yes ✓ No                         | Corresponding Author's Name  Marc A. Schneider |  |  |
| 5. Manuscript Title<br>Comprehensive serial biobanking in a                                                                                                                                                                                                                                                                                                                                                                                         | dvanced NSCLC: feasibility,      | challenges and perspectives                    |  |  |
| 6. Manuscript Identifying Number (if you k                                                                                                                                                                                                                                                                                                                                                                                                          | (now it)                         |                                                |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                  |                                                |  |  |
| Section 2. The Work Under (                                                                                                                                                                                                                                                                                                                                                                                                                         | Consideration for Public         | ation                                          |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                                                                       |                                  |                                                |  |  |
| Section 3. Polosont Granuic                                                                                                                                                                                                                                                                                                                                                                                                                         |                                  |                                                |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                                  |                                                |  |  |
| Section 4. Intellectual Prope                                                                                                                                                                                                                                                                                                                                                                                                                       | erty Patents & Copyrig           | ıhts                                           |  |  |
| Do you have any patents, whether pla                                                                                                                                                                                                                                                                                                                                                                                                                |                                  |                                                |  |  |

Herpel 2



| Section 5.                  |                                                                                                                                                                                                       |
|-----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section 5.                  | Relationships not covered above                                                                                                                                                                       |
|                             | ationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?                                                   |
| Yes, the follow             | ing relationships/conditions/circumstances are present (explain below):                                                                                                                               |
| ✓ No other relation         | onships/conditions/circumstances that present a potential conflict of interest                                                                                                                        |
|                             | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>nals may ask authors to disclose further information about reported relationships. |
| Section 6.                  | Disclosure Statement                                                                                                                                                                                  |
| Based on the abov<br>below. | re disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                            |
| Dr. Herpel has not          | thing to disclose.                                                                                                                                                                                    |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Herpel 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

ony, employment, or other affiliations patent

Hummler 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Identifying Inform         | ation                             |                                             |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-----------------------------------|---------------------------------------------|--|
| 1. Given Name (Fii<br>Simone                                                                                                                                                                                                                                                                                                                                                                                                                        | rst Name)                  | 2. Surname (Last Name)<br>Hummler | 3. Date<br>24-April-2020                    |  |
| 4. Are you the cor                                                                                                                                                                                                                                                                                                                                                                                                                                  | responding author?         | Yes ✓ No                          | Corresponding Author's Name  Marc Schneider |  |
| 5. Manuscript Title<br>Comprehensive<br>challenges and p                                                                                                                                                                                                                                                                                                                                                                                            | serial biobanking in ad    | vanced NSCLC: feasibility,        |                                             |  |
| 6. Manuscript Ider<br>TLCR-20-137                                                                                                                                                                                                                                                                                                                                                                                                                   | ntifying Number (if you kn | ow it)                            |                                             |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     | l .                        |                                   |                                             |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                          | The Work Under Co          | onsideration for Public           | ation                                       |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                                                                       |                            |                                   |                                             |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant financial         | activities outside the s          | ubmitted work.                              |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                            |                                   |                                             |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Intellectual Proper        | ty Patents & Copyrig              | hts                                         |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            |                                   | oadly relevant to the work? Yes V No        |  |

Hummler 2



| Section 5.                |                                                                                                                                                                                                     |
|---------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section 5.                | Relationships not covered above                                                                                                                                                                     |
|                           | ationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?                                                 |
| Yes, the followi          | ng relationships/conditions/circumstances are present (explain below):                                                                                                                              |
| ✓ No other relation       | onships/conditions/circumstances that present a potential conflict of interest                                                                                                                      |
|                           | uscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>als may ask authors to disclose further information about reported relationships. |
| Section 6.                | Disclosure Statement                                                                                                                                                                                |
| Based on the above below. | e disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                           |
| Dr. Hummler has r         | nothing to disclose.                                                                                                                                                                                |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Hummler 3



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Klingmüller 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Identifying Inform         | nation                                |                                               |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|---------------------------------------|-----------------------------------------------|--|
| 1. Given Name (First Name) Ursula  4. Are you the corresponding author?                                                                                                                                                                                                                                                                                                                                                                             |                            | 2. Surname (Last Name)<br>Klingmüller | 3. Date<br>24-April-2020                      |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            | Yes ✓ No                              | Corresponding Author's Name<br>Marc Schneider |  |
| 5. Manuscript Title<br>Comprehensive s                                                                                                                                                                                                                                                                                                                                                                                                              |                            | vanced NSCLC: feasibility,            | challenges and perspectives                   |  |
| 6. Manuscript Iden                                                                                                                                                                                                                                                                                                                                                                                                                                  | ntifying Number (if you kn | now it)                               |                                               |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            |                                       |                                               |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                          | The Work Under Co          | onsideration for Public               | cation                                        |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  Volume                                                                   |                            |                                       |                                               |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            |                                       |                                               |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant financial         | activities outside the s              | ubmitted work.                                |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                            |                                       |                                               |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            |                                       |                                               |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Intellectual Proper        | rty Patents & Copyric                 | phts                                          |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                     | patents, whether plan      | ned, pending or issued, br            | oadly relevant to the work? Yes V No          |  |

Klingmüller 2



| Section 5. Relationships not severed above                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Relationships not covered above                                                                                                                                                                                                      |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |
| Dr. Klingmüller has nothing to disclose.                                                                                                                                                                                             |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Klingmüller 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your

Kuon 1



| Section 1. Identifying Inform                                                                                                                                                                                                                                                                                                                                                                                                                         | nation                         |                                                 |  |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|-------------------------------------------------|--|--|
| Given Name (First Name)  Jonas                                                                                                                                                                                                                                                                                                                                                                                                                        | 2. Surname (Last Name)<br>Kuon | 3. Date<br>24-April-2020                        |  |  |
| 4. Are you the corresponding author?                                                                                                                                                                                                                                                                                                                                                                                                                  | ☐ Yes ✓ No                     | Corresponding Author's Name<br>Marc A Schneider |  |  |
| 5. Manuscript Title<br>Comprehensive serial biobanking in ac                                                                                                                                                                                                                                                                                                                                                                                          | Ivanced NSCLC: feasibility,    | challenges and perspectives                     |  |  |
| 6. Manuscript Identifying Number (if you k                                                                                                                                                                                                                                                                                                                                                                                                            | now it)                        |                                                 |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                                |                                                 |  |  |
| Section 2. The Work Under C                                                                                                                                                                                                                                                                                                                                                                                                                           | onsideration for Public        | cation                                          |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                                                                         |                                |                                                 |  |  |
| , , , , , , , , , , , , , , , , , , , ,                                                                                                                                                                                                                                                                                                                                                                                                               |                                |                                                 |  |  |
| Section 3. Relevant financial                                                                                                                                                                                                                                                                                                                                                                                                                         | activities outside the s       | submitted work.                                 |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V No |                                |                                                 |  |  |
| •                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                |                                                 |  |  |
| Section 4. Intellectual Prope                                                                                                                                                                                                                                                                                                                                                                                                                         | rty Patents & Copyric          | ghts                                            |  |  |
| Do you have any patents, whether plan                                                                                                                                                                                                                                                                                                                                                                                                                 | nned, pending or issued, br    | roadly relevant to the work? Yes V No           |  |  |

Kuon 2



| Section 5.       |                                                                                                                                                                                                                                       |  |  |  |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|
|                  | Relationships not covered above                                                                                                                                                                                                       |  |  |  |
|                  | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?                                                                               |  |  |  |
| Yes, the follo   | wing relationships/conditions/circumstances are present (explain below):                                                                                                                                                              |  |  |  |
| ✓ No other rela  | tionships/conditions/circumstances that present a potential conflict of interest                                                                                                                                                      |  |  |  |
|                  | At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |  |  |  |
| Section 6.       | Disclosure Statement                                                                                                                                                                                                                  |  |  |  |
| Based on the abo | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                                                           |  |  |  |
| Dr. Kuon has no  | thing to disclose.                                                                                                                                                                                                                    |  |  |  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Kuon 3

# Potential Conflicts of Interest of Claus Peter Heussel

### **Employment or Leadership Position**

- Head of Diagnostic and Interv Radiology with Nuclear Medicine, Thoraxklinik Heidelberg
- Member of the German Center for Lung Research

### Stock ownership in medical industry: GSK

Patent: Method and Device For Representing the Microstructure of the Lungs. IPC8 Class: AA61B5055FI, PAN: 20080208038, Inventors: W Schreiber, U Wolf, AW Scholz, CP Heussel

#### Consultation or other fees

Schering-Plough 2009, 2010 Pfizer 2008-2014 Basilea 2008, 2009, 2010 Boehringer Ingelheim 2010-2014 Novartis 2010, 2012, 2014 Roche 2010 Astellas 2011, 2012 Gilead 2011-2015 MSD 2011-2013 Lilly 2011 Intermune 2013-2014

### **Research funding**

Fresenius 2013, 2014

Siemens 2012-2014 Pfizer 2012-2014 MeVis 2012, 2013 Boehringer Ingelheim 2014 German Center for Lung Research 2011ff

### **Expert testimony:** No

Tobacco Industry: No relation

#### Lecture fees

Gilead 2008-2014

Essex 2008, 2009, 2010 Schering-Plough 2008, 2009, 2010 AstraZeneca 2008-2012 Lilly 2008, 2009, 2012 Roche 2008, 2009 MSD 2009-2014 Pfizer 2010-2014 Bracco 2010, 2011 MEDA Pharma 2011 Intermune 2011-2014 Chiesi 2012 Siemens 2012 Covidien 2012 Pierre Fabre 2012 Boehringer Ingelheim 2012, 2013 Grifols 2012 Novartis 2013-2016 Basilea 2015, 2016 Bayer 2016

### **Comitee membership**

- Chest working group of the German Roentgen society
  - National guidelines: bronchial carcinoma, mesothelioma, COPD, screening for bronchial carcinoma, CT and MR imaging of the chest, Pneumonia, HAP
- Consultant of ECIL-3, ECCMID, EORTC/MSG
  - · Guideline for diagnosis of infections in immunocompromized hosts
- Founding member of the working team in infections in immunocompromized hosts of the German society of Hematology/Oncology
  - · Guideline for diagnosis of infections in immunocompromized hosts
- Faculty member of European Society of Thoracic Radiology (ESTI), European Respiratory Society (ERS), and member in EIBALL (European Imaging Biomarkers Alliance)
- Editor of "Medizinische Klinik, Intensivmedizin und Notfallmedizin", at Dr. Dietrich Steinkopff (Springer) publishing

Heidelberg, 24.4.2020, Prof. Dr. C.P. Heußel



#### Instructions

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed: The patent has been licensed to an entit

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Eberhardt 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                            | Identifying Inform         | nation                              |                                                 |  |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|-------------------------------------|-------------------------------------------------|--|
| 1. Given Name (First Name)<br>Ralf                                                                                                                                                                                                                                                                                                                                                                                                                    |                            | 2. Surname (Last Name)<br>Eberhardt | 3. Date<br>24-April-2020                        |  |
| 4. Are you the cor                                                                                                                                                                                                                                                                                                                                                                                                                                    | responding author?         | Yes ✓ No                            | Corresponding Author's Name<br>Marc A Schneider |  |
| 5. Manuscript Title<br>Comprehensive                                                                                                                                                                                                                                                                                                                                                                                                                  |                            | vanced NSCLC: feasibility,          | challenges and perspectives                     |  |
| 6. Manuscript Ide                                                                                                                                                                                                                                                                                                                                                                                                                                     | ntifying Number (if you kr | now it)                             |                                                 |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                       |                            |                                     | -                                               |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                            | The Work Under C           | onsideration for Public             | ration                                          |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                                                                         |                            |                                     |                                                 |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                       | ı                          |                                     |                                                 |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                            | Relevant financial         | activities outside the s            | ubmitted work.                                  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes V No |                            |                                     |                                                 |  |
| c and any rea                                                                                                                                                                                                                                                                                                                                                                                                                                         | 2.2 coco o. interv         |                                     |                                                 |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                            | lotelle to de              | . Division of Control               | d.c.                                            |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                       | Intellectual Propei        | rty Patents & Copyri <u>c</u>       | ints ————————————————————————————————————       |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                       | patents, whether plan      | ned, pending or issued, br          | oadly relevant to the work? Yes V No            |  |

Eberhardt 2



| Section 5.                   |                                                                                                                                                                                                    |
|------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| R                            | elationships not covered above                                                                                                                                                                     |
|                              | tionships or activities that readers could perceive to have influenced, or that give the appearance of ing, what you wrote in the submitted work?                                                  |
| Yes, the following           | ng relationships/conditions/circumstances are present (explain below):                                                                                                                             |
| ✓ No other relation          | nships/conditions/circumstances that present a potential conflict of interest                                                                                                                      |
|                              | sscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>Is may ask authors to disclose further information about reported relationships. |
| Section 6. D                 | isclosure Statement                                                                                                                                                                                |
| Based on the above<br>below. | disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                            |
| Dr. Eberhardt has n          | othing to disclose.                                                                                                                                                                                |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Eberhardt 3



### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

### Identifying information.

### 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

### 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Herth 1



|                                      | Section 1. Identifying Information                                                                                                                                                                                                                                                                                                                                                            | ation                           |                        |          |     |  |  |
|--------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|------------------------|----------|-----|--|--|
|                                      | 1. Given Name (First Name)<br>Felix JF                                                                                                                                                                                                                                                                                                                                                        | 2. Surname (Last Name)<br>Herth | ,                      |          |     |  |  |
| 4. Are you the corresponding author? |                                                                                                                                                                                                                                                                                                                                                                                               |                                 |                        |          |     |  |  |
|                                      | 5. Manuscript Title<br>Comprehensive serial biobanking in adv                                                                                                                                                                                                                                                                                                                                 | ranced NSCLC: feasibility,      | challanges and perspec | tives    |     |  |  |
|                                      | 6. Manuscript Identifying Number (if you kno                                                                                                                                                                                                                                                                                                                                                  | ow it)                          |                        |          |     |  |  |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                               |                                 | _                      |          |     |  |  |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                               |                                 |                        |          |     |  |  |
|                                      | Section 2. The Work Under Co                                                                                                                                                                                                                                                                                                                                                                  | nsideration for Public          | ation                  |          |     |  |  |
|                                      | Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?                                                                                                                                                                                                                                                                 |                                 |                        |          | for |  |  |
|                                      | Are there any relevant conflicts of interest? Yes Vo                                                                                                                                                                                                                                                                                                                                          |                                 |                        |          |     |  |  |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                               |                                 |                        |          |     |  |  |
|                                      | Section 3. Relevant financial a                                                                                                                                                                                                                                                                                                                                                               | activities outside the s        | submitted work         |          |     |  |  |
|                                      |                                                                                                                                                                                                                                                                                                                                                                                               |                                 |                        |          |     |  |  |
|                                      | Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> . |                                 |                        |          |     |  |  |
|                                      | Are there any relevant conflicts of interes                                                                                                                                                                                                                                                                                                                                                   |                                 |                        |          |     |  |  |
|                                      | If yes, please fill out the appropriate info                                                                                                                                                                                                                                                                                                                                                  | rmation below.                  |                        |          |     |  |  |
|                                      | Name of Entity                                                                                                                                                                                                                                                                                                                                                                                | Grant? Personal Nor             | n-Financial Other?     | Comments |     |  |  |
| U                                    | ptake                                                                                                                                                                                                                                                                                                                                                                                         |                                 |                        |          |     |  |  |
| В                                    | TG                                                                                                                                                                                                                                                                                                                                                                                            |                                 |                        |          |     |  |  |
| С                                    | llympus                                                                                                                                                                                                                                                                                                                                                                                       |                                 |                        |          |     |  |  |
| P                                    | ulmonx                                                                                                                                                                                                                                                                                                                                                                                        |                                 |                        |          |     |  |  |
| D                                    | ocho                                                                                                                                                                                                                                                                                                                                                                                          |                                 |                        |          |     |  |  |

Herth 2



| Section 4. Intellectual Property Patents & Copyrights                                                                                                                                                                                 |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume                                                                                                                                 |
| Section 5. Relationships not covered above                                                                                                                                                                                            |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                             |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                                |
| No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                         |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                       |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                     |
| Dr. Herth reports personal fees from Uptake, personal fees from BTG, personal fees from Olympus, personal fees from Pulmonx, personal fees from Roche, outside the submitted work; .                                                  |

### **Evaluation and Feedback**

 $Please\ visit\ \underline{http://www.icmje.org/cgi-bin/feedback}\ to\ provide\ feedback\ on\ your\ experience\ with\ completing\ this\ form.$ 

Herth 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Winter 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Identifying Inform                  | nation                           |                                                  |  |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|----------------------------------|--------------------------------------------------|--|--|--|
| 1. Given Name (First<br>Hauke                                                                                                                                                                                                                                                                                                                                                                                                                       | st Name)                            | 2. Surname (Last Name)<br>Winter | 3. Date<br>24-April-2020                         |  |  |  |
| 4. Are you the corresponding author?  Yes  No                                                                                                                                                                                                                                                                                                                                                                                                       |                                     |                                  | Corresponding Author's Name<br>Marc A. Schneider |  |  |  |
| 5. Manuscript Title<br>Comprehensive s                                                                                                                                                                                                                                                                                                                                                                                                              | erial biobanking in ad <sup>,</sup> | vanced NSCLC: feasibility,       | challenges and perspectives                      |  |  |  |
| 6. Manuscript Iden<br>TLCR-20-137                                                                                                                                                                                                                                                                                                                                                                                                                   | tifying Number (if you kn           | now it)                          |                                                  |  |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                     |                                  | -                                                |  |  |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                          | The Work Under Co                   | onsideration for Public          | ation                                            |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                                                                       |                                     |                                  |                                                  |  |  |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant financial                  | activities outside the s         | ubmitted work.                                   |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                                     |                                  |                                                  |  |  |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Intellectual Proper                 | ty Patents & Copyrig             | ıhts                                             |  |  |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                     | patents, whether plan               | ned, pending or issued, br       | oadly relevant to the work? Yes V No             |  |  |  |

Winter 2



| Section 5.                  |                                                                                                                                                                                                         |
|-----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section 5.                  | Relationships not covered above                                                                                                                                                                         |
|                             | ationships or activities that readers could perceive to have influenced, or that give the appearance of cing, what you wrote in the submitted work?                                                     |
| Yes, the following          | ing relationships/conditions/circumstances are present (explain below):                                                                                                                                 |
| ✓ No other relation         | onships/conditions/circumstances that present a potential conflict of interest                                                                                                                          |
|                             | nuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>I pals may ask authors to disclose further information about reported relationships. |
| Section 6.                  | Disclosure Statement                                                                                                                                                                                    |
| Based on the abov<br>below. | re disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                              |
| Dr. Winter has not          | thing to disclose.                                                                                                                                                                                      |

# **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Winter 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

### 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

Licensed. The potent has been sounded by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Bischoff 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Identifying Inform         | nation                             |                                                 |  |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|------------------------------------|-------------------------------------------------|--|--|--|
| 1. Given Name (Fir<br>Helge                                                                                                                                                                                                                                                                                                                                                                                                                         | st Name)                   | 2. Surname (Last Name)<br>Bischoff | 3. Date<br>24-April-2020                        |  |  |  |
| 4. Are you the corr                                                                                                                                                                                                                                                                                                                                                                                                                                 | esponding author?          | Yes ✓ No                           | Corresponding Author's Name<br>Marc A Schneider |  |  |  |
| 5. Manuscript Title<br>Comprehensive s                                                                                                                                                                                                                                                                                                                                                                                                              |                            | vanced NSCLC: feasibility,         | challenges and perspectives                     |  |  |  |
| 6. Manuscript Iden                                                                                                                                                                                                                                                                                                                                                                                                                                  | ntifying Number (if you kr | now it)                            |                                                 |  |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            |                                    |                                                 |  |  |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                          | The Work Under C           | onsideration for Publi             | cation                                          |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                                                                       |                            |                                    |                                                 |  |  |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant financial         | activities outside the             | submitted work.                                 |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                            |                                    |                                                 |  |  |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Intellectual Proper        | rty Patents & Copyri               | ghts                                            |  |  |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                     | patents, whether plan      | ned, pending or issued, b          | roadly relevant to the work? Yes V No           |  |  |  |

Bischoff 2



| Section 5. Polationships not sovered above                                                                                                                                                                                           |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Relationships not covered above                                                                                                                                                                                                      |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |
| Dr. Bischoff has nothing to disclose.                                                                                                                                                                                                |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Bischoff 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your



| Section 1.                           | Identifying Inform                                 | ation     |                    |                         |           |                                                                             |        |
|--------------------------------------|----------------------------------------------------|-----------|--------------------|-------------------------|-----------|-----------------------------------------------------------------------------|--------|
| 1. Given Name (Fir<br>Albrecht       |                                                    |           | ne (Last Nam<br>er | ie)                     |           | 3. Date<br>24-April-2020                                                    |        |
| 4. Are you the cor                   | responding author?                                 | Yes       | <b>√</b> No        | Correspond<br>Marc Schn | _         | or's Name                                                                   |        |
| 5. Manuscript Title<br>Comprehensive | e<br>serial biobanking in ad                       | vanced NS | CLC: feasib        | ility, challenges       | and persp | pectives                                                                    |        |
| 6. Manuscript Ider<br>TLCR-20-137    | ntifying Number (if you kn                         | ow it)    |                    |                         |           |                                                                             |        |
|                                      |                                                    |           |                    |                         |           |                                                                             |        |
| Section 2.                           | The Work Under Co                                  | onsiderat | ion for Pu         | ıblication              |           |                                                                             |        |
|                                      | ubmitted work (including                           |           |                    |                         |           | ent, commercial, private foundation,<br>udy design, manuscript preparation, |        |
| •                                    | evant conflicts of intere                          |           |                    | lo                      |           |                                                                             |        |
|                                      | out the appropriate info<br>be removed by pressing |           |                    | have more than          | one enti  | ty press the "ADD" button to add                                            | a row. |
| Name of Institut                     | ion/Company                                        | Grant?    | Personal<br>Fees?  | Non-Financial Support?  | Other?    | Comments                                                                    |        |
| Astra Zeneca                         |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| lovartis                             |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| BMS                                  |                                                    | <b>✓</b>  | <b>✓</b>           |                         |           |                                                                             |        |
| MSD                                  |                                                    |           | $\checkmark$       |                         |           |                                                                             |        |
| Bayer                                |                                                    | <b>✓</b>  | $\checkmark$       |                         |           |                                                                             |        |
| eattle Genetics                      |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| akeda                                |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| ili Lilly                            |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| llumina                              |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| hermo Fisher                         |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| Chugai                               |                                                    | <b>✓</b>  |                    |                         |           |                                                                             |        |
| Roche                                |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| fizer                                |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |
| anssen                               |                                                    |           | <b>✓</b>           |                         |           |                                                                             |        |



| Section 3. Relevant financial activities outside the submitted work.                                                                                                                                                                                                                                                                                                                                                                                                                      |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo                                       |
| Section 4. Intellectual Property Patents & Copyrights                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| Do you have any patents, whether planned, pending or issued, broadly relevant to the work? Yes Volume                                                                                                                                                                                                                                                                                                                                                                                     |
| Section 5. Relationships not covered above                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                                                                                                                                                                                                                                                                                 |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                                                                                                                                                                                                                                                                                    |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                                                                                                                                                                                                                                                                           |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements. On occasion, journals may ask authors to disclose further information about reported relationships.                                                                                                                                                                                                                                                     |
| Section 6. Disclosure Statement                                                                                                                                                                                                                                                                                                                                                                                                                                                           |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                                                                                                                                                                                                                                                                         |
| Dr. Stenzinger reports personal fees from Astra Zeneca, personal fees from Novartis, grants and personal fees from BMS, personal fees from MSD, grants and personal fees from Bayer, personal fees from Seattle Genetics, personal fees from Takeda, personal fees from Eli Lilly, personal fees from Illumina, personal fees from Thermo Fisher, grants from Chugai, personal fees from Roche, personal fees from Pfizer, personal fees from Janssen, during the conduct of the study; . |



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

Royalties: Funds are coming in to you or your institution due to your

Reck 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Identifying Inform         | ation                          |                                                  |  |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------|--------------------------------|--------------------------------------------------|--|--|--|
| 1. Given Name (Fir<br>Martin                                                                                                                                                                                                                                                                                                                                                                                                                        | rst Name)                  | 2. Surname (Last Name)<br>Reck | 3. Date<br>30-August-2019                        |  |  |  |
| 4. Are you the corr                                                                                                                                                                                                                                                                                                                                                                                                                                 | responding author?         | Yes ✓ No                       | Corresponding Author's Name<br>Marc A. Schneider |  |  |  |
| 5. Manuscript Title<br>Comprehensive                                                                                                                                                                                                                                                                                                                                                                                                                |                            | vanced NSCLC: feasibility,     | challenges and perspectives                      |  |  |  |
| 6. Manuscript Ider<br>TLCR-20-137                                                                                                                                                                                                                                                                                                                                                                                                                   | ntifying Number (if you kr | now it)                        |                                                  |  |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                            |                                |                                                  |  |  |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                          | The Work Under Co          | onsideration for Public        | ation                                            |  |  |  |
| Did you or your institution <b>at any time</b> receive payment or services from a third party (government, commercial, private foundation, etc.) for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)?  Are there any relevant conflicts of interest?  Yes  No                                                                       |                            |                                |                                                  |  |  |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant financial         | activities outside the s       | ubmitted work.                                   |  |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                            |                                |                                                  |  |  |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Intellectual Proper        | ty Patents & Copyric           | jhts                                             |  |  |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                     | patents, whether plan      | ned, pending or issued, br     | oadly relevant to the work? Yes V No             |  |  |  |

Reck 2



| Section 5.                 |                                                                                                                                                                                                         |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                            | Relationships not covered above                                                                                                                                                                         |
|                            | elationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?                                                 |
| Yes, the follo             | wing relationships/conditions/circumstances are present (explain below):                                                                                                                                |
| ✓ No other rela            | tionships/conditions/circumstances that present a potential conflict of interest                                                                                                                        |
|                            | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |
| Section 6.                 | Disclosure Statement                                                                                                                                                                                    |
| Based on the abo<br>below. | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                             |
| Dr. Reck has not           | hing to disclose.                                                                                                                                                                                       |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Reck 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Huber 1



| Section 1.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Identifying Inform                                              | nation                                   |                                          |                                                                                                         |  |  |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------|------------------------------------------|---------------------------------------------------------------------------------------------------------|--|--|
| 1. Given Name (Fi<br>Rudolf                                                                                                                                                                                                                                                                                                                                                                                                                         | rst Name)                                                       | 2. Surname (Last Name)<br>Huber          |                                          | 3. Date<br>24-April-2020                                                                                |  |  |
| 4. Are you the cor                                                                                                                                                                                                                                                                                                                                                                                                                                  | responding author?                                              | ☐ Yes ✓ No                               | Corresponding Autho<br>Marc A. Schneider | r's Name                                                                                                |  |  |
| 5. Manuscript Title<br>Comprehensive                                                                                                                                                                                                                                                                                                                                                                                                                |                                                                 | vanced NSCLC: feasibility                | ı, challenges and perspe                 | ectives                                                                                                 |  |  |
| 6. Manuscript Ider<br>TLCR-20-137                                                                                                                                                                                                                                                                                                                                                                                                                   | ntifying Number (if you kr                                      | now it)                                  |                                          |                                                                                                         |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     | ı                                                               |                                          |                                          |                                                                                                         |  |  |
| Section 2.                                                                                                                                                                                                                                                                                                                                                                                                                                          | The Work Under Co                                               | onsideration for Publ                    | ication                                  |                                                                                                         |  |  |
| any aspect of the s<br>statistical analysis,<br>Are there any rel<br>If yes, please fill o                                                                                                                                                                                                                                                                                                                                                          | ubmitted work (including<br>etc.)?<br>evant conflicts of intere | est? Yes No<br>prmation below. If you ha | data monitoring board, stu               | ent, commercial, private foundation, etc.) for ady design, manuscript preparation, etc.) for add a row. |  |  |
| Name of Institut                                                                                                                                                                                                                                                                                                                                                                                                                                    | ion/Company                                                     | Grant? Personal No                       | on-Financial Other?                      | Comments                                                                                                |  |  |
| German Center for Lu                                                                                                                                                                                                                                                                                                                                                                                                                                | ung Research DZL                                                | <b>✓</b>                                 |                                          |                                                                                                         |  |  |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                     | ı                                                               |                                          |                                          |                                                                                                         |  |  |
| Section 3.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Relevant financial                                              | activities outside the                   | submitted work.                          |                                                                                                         |  |  |
| Place a check in the appropriate boxes in the table to indicate whether you have financial relationships (regardless of amount of compensation) with entities as described in the instructions. Use one line for each entity; add as many lines as you need by clicking the "Add +" box. You should report relationships that were <b>present during the 36 months prior to publication</b> .  Are there any relevant conflicts of interest? Yes Vo |                                                                 |                                          |                                          |                                                                                                         |  |  |
| Section 4.                                                                                                                                                                                                                                                                                                                                                                                                                                          | Intellectual Proper                                             | ty Patents & Copyr                       | ights                                    |                                                                                                         |  |  |
| Do you have any                                                                                                                                                                                                                                                                                                                                                                                                                                     | patents, whether plan                                           | ned, pending or issued, l                | proadly relevant to the v                | work? Yes 🗸 No                                                                                          |  |  |

Huber 2



| Section 5.                 |                                                                                                                                                                                                         |
|----------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Section 5.                 | Relationships not covered above                                                                                                                                                                         |
|                            | relationships or activities that readers could perceive to have influenced, or that give the appearance of encing, what you wrote in the submitted work?                                                |
| Yes, the follo             | wing relationships/conditions/circumstances are present (explain below):                                                                                                                                |
| ✓ No other rela            | tionships/conditions/circumstances that present a potential conflict of interest                                                                                                                        |
|                            | anuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements<br>rnals may ask authors to disclose further information about reported relationships. |
|                            |                                                                                                                                                                                                         |
| Section 6.                 | Disclosure Statement                                                                                                                                                                                    |
| Based on the abo<br>below. | ove disclosures, this form will automatically generate a disclosure statement, which will appear in the box                                                                                             |
| Dr. Huber report           | ts grants from German Center for Lung Research DZL, during the conduct of the study; .                                                                                                                  |

### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Huber 3



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued **Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether

earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent



Section 1.

# **ICMJE Form for Disclosure of Potential Conflicts of Interest**

| Section 1. Identifying Inform                                                                                                                                             | ation                           |                             |                                                                                                                                            |     |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------|-----------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1. Given Name (First Name)<br>Michael                                                                                                                                     | 2. Surname (Last Name<br>Thomas | e)                          | 3. Date<br>30-April-2020                                                                                                                   |     |
| 4. Are you the corresponding author?                                                                                                                                      | Yes ✓ No                        | Correspondi<br>Schneider, I | ng Author's Name<br>Marc                                                                                                                   |     |
| 5. Manuscript Title<br>Comprehensive serial biobanking in adv                                                                                                             | vanced NSCLC: feasibil          | lity, challenges an         | d perspectives                                                                                                                             |     |
| 6. Manuscript Identifying Number (if you kn<br>TLCR-20-137                                                                                                                | ow it)                          |                             |                                                                                                                                            |     |
|                                                                                                                                                                           |                                 |                             |                                                                                                                                            |     |
| Section 2. The Work Under Co                                                                                                                                              | onsideration for Pu             | blication                   |                                                                                                                                            |     |
| Did you or your institution <b>at any time</b> receivany aspect of the submitted work (including statistical analysis, etc.)?  Are there any relevant conflicts of intere | but not limited to grants       | s, data monitoring l        | overnment, commercial, private foundation, etc.) poard, study design, manuscript preparation,                                              | for |
| Section 3. Relevant financial a                                                                                                                                           | activities outside th           | he submitted w              | ork.                                                                                                                                       |     |
| of compensation) with entities as describ                                                                                                                                 | bed in the instructions         | s. Use one line for         | e financial relationships (regardless of amour<br>each entity; add as many lines as you need b<br>ring the 36 months prior to publication. |     |
| Are there any relevant conflicts of intere                                                                                                                                | est? ✓ Yes N                    | lo                          |                                                                                                                                            |     |
| If yes, please fill out the appropriate info                                                                                                                              | ormation below.                 |                             |                                                                                                                                            |     |
| Name of Entity                                                                                                                                                            | Grant? Personal Fees?           | Non-Financial Support?      | Other? Comments                                                                                                                            |     |
| AstraZeneca                                                                                                                                                               | <b>✓</b>                        | <b>✓</b>                    |                                                                                                                                            |     |
| Bristol-Myers Squibb                                                                                                                                                      | <b>✓</b>                        | <b>✓</b>                    |                                                                                                                                            |     |
| Boehringer Ingelheim                                                                                                                                                      |                                 | <b>✓</b>                    |                                                                                                                                            |     |
| Celgene                                                                                                                                                                   |                                 | <b>✓</b>                    |                                                                                                                                            |     |
| Chugai                                                                                                                                                                    |                                 | ✓                           |                                                                                                                                            |     |
| Lilly                                                                                                                                                                     |                                 | $\checkmark$                |                                                                                                                                            |     |
| MSD                                                                                                                                                                       |                                 | <b>✓</b>                    |                                                                                                                                            |     |
| Novartis                                                                                                                                                                  |                                 | <b>✓</b>                    |                                                                                                                                            |     |



| Name of Entity                                                                        | Grant?      | Personal Fees? | Non-Financial Support? | Other?      | Comments                             |        |
|---------------------------------------------------------------------------------------|-------------|----------------|------------------------|-------------|--------------------------------------|--------|
| Pfizer                                                                                |             | <b>✓</b>       | <b>√</b>               |             |                                      |        |
| Roche                                                                                 | <b>✓</b>    | <b>✓</b>       | ✓                      |             |                                      |        |
| Takeda                                                                                | <b>✓</b>    | <b>✓</b>       | <b>✓</b>               |             |                                      |        |
| Section 4. Intellectual Propert                                                       | v Pate      | ents & Coi     | pyriahts               |             |                                      |        |
| Do you have any patents, whether plann                                                |             |                |                        | int to the  | work? Yes 🗸 No                       |        |
| Section 5. Relationships not o                                                        | overed      | above          |                        |             |                                      |        |
| Are there other relationships or activities potentially influencing, what you wrote i |             |                |                        | influenced  | d, or that give the appearance of    |        |
| Yes, the following relationships/cond                                                 |             |                | •                      |             |                                      |        |
| At the time of manuscript acceptance, jo<br>On occasion, journals may ask authors to  | urnals wi   | Il ask autho   | ors to confirm and     | d, if neces | sary, update their disclosure staten | nents. |
| Section 6. Disclosure Stateme                                                         | nt          |                |                        |             |                                      |        |
| Based on the above disclosures, this forn below.                                      | າ will auto | omatically (   | generate a disclos     | sure state  | ment, which will appear in the box   |        |

Dr. Thomas reports grants, personal fees and non-financial support from AstraZeneca, grants, personal fees and non-financial support from Bristol-Myers Squibb, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Chugai, personal fees and non-financial support from Chugai, personal fees and non-financial support from MSD, personal fees and non-financial support from Novartis, personal fees and non-financial support from Pfizer, grants, personal fees and non-financial support from Roche, grants, personal fees and non-financial support from Takeda, outside the submitted work;



#### **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.



#### **Instructions**

The purpose of this form is to provide readers of your manuscript with information about your other interests that could influence how they receive and understand your work. The form is designed to be completed electronically and stored electronically. It contains programming that allows appropriate data display. Each author should submit a separate form and is responsible for the accuracy and completeness of the submitted information. The form is in six parts.

# Identifying information.

# 2. The work under consideration for publication.

This section asks for information about the work that you have submitted for publication. The time frame for this reporting is that of the work itself, from the initial conception and planning to the present. The requested information is about resources that you received, either directly or indirectly (via your institution), to enable you to complete the work. Checking "No" means that you did the work without receiving any financial support from any third party -- that is, the work was supported by funds from the same institution that pays your salary and that institution did not receive third-party funds with which to pay you. If you or your institution received funds from a third party to support the work, such as a government granting agency, charitable foundation or commercial sponsor, check "Yes".

## 3. Relevant financial activities outside the submitted work.

This section asks about your financial relationships with entities in the bio-medical arena that could be perceived to influence, or that give the appearance of potentially influencing, what you wrote in the submitted work. You should disclose interactions with ANY entity that could be considered broadly relevant to the work. For example, if your article is about testing an epidermal growth factor receptor (EGFR) antagonist in lung cancer, you should report all associations with entities pursuing diagnostic or therapeutic strategies in cancer in general, not just in the area of EGFR or lung cancer.

Report all sources of revenue paid (or promised to be paid) directly to you or your institution on your behalf over the 36 months prior to submission of the work. This should include all monies from sources with relevance to the submitted work, not just monies from the entity that sponsored the research. Please note that your interactions with the work's sponsor that are outside the submitted work should also be listed here. If there is any question, it is usually better to disclose a relationship than not to do so.

For grants you have received for work outside the submitted work, you should disclose support ONLY from entities that could be perceived to be affected financially by the published work, such as drug companies, or foundations supported by entities that could be perceived to have a financial stake in the outcome. Public funding sources, such as government agencies, charitable foundations or academic institutions, need not be disclosed. For example, if a government agency sponsored a study in which you have been involved and drugs were provided by a pharmaceutical company, you need only list the pharmaceutical company.

# 4. Intellectual Property.

This section asks about patents and copyrights, whether pending, issued, licensed and/or receiving royalties.

# Relationships not covered above.

Use this section to report other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work.

#### Definitions.

**Entity:** government agency, foundation, commercial sponsor, academic institution, etc.

**Grant:** A grant from an entity, generally [but not always] paid to your organization

**Personal Fees:** Monies paid to you for services rendered, generally honoraria, royalties, or fees for consulting, lectures, speakers bureaus, expert testimony, employment, or other affiliations

**Non-Financial Support:** Examples include drugs/equipment supplied by the entity, travel paid by the entity, writing assistance, administrative support, etc.

Other: Anything not covered under the previous three boxes

**Pending:** The patent has been filed but not issued

**Issued:** The patent has been issued by the agency

**Licensed:** The patent has been licensed to an entity, whether earning royalties or not

**Royalties:** Funds are coming in to you or your institution due to your patent

Schneider 1



| Section 1.                                                                                 | Identifying Inform                                              | ation                                                           |                                          |                  |                                                                                                            |  |  |  |
|--------------------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------------------------------------------------------------|------------------------------------------|------------------|------------------------------------------------------------------------------------------------------------|--|--|--|
| 1. Given Name (Fi<br>Marc Andre                                                            | rst Name)                                                       | 2. Surname (Last Name)<br>Schneider                             |                                          |                  | 3. Date<br>24-April-2020                                                                                   |  |  |  |
| 4. Are you the cor                                                                         | responding author?                                              | ✓ Yes No                                                        | ✓ Yes No                                 |                  |                                                                                                            |  |  |  |
| 5. Manuscript Title<br>Comprehensive                                                       |                                                                 | vanced NSCLC: feasibilit                                        | y, challenges a                          | and perspectiv   | res                                                                                                        |  |  |  |
| 6. Manuscript Ider<br>TLCR-20-137                                                          | ntifying Number (if you kn                                      | ow it)                                                          |                                          |                  |                                                                                                            |  |  |  |
| Section 2                                                                                  |                                                                 |                                                                 |                                          |                  |                                                                                                            |  |  |  |
| Section 2.                                                                                 | The Work Under Co                                               | onsideration for Pub                                            | lication                                 |                  |                                                                                                            |  |  |  |
| any aspect of the s<br>statistical analysis,<br>Are there any rel<br>If yes, please fill o | ubmitted work (including<br>etc.)?<br>evant conflicts of intere | but not limited to grants, est? Yes No ermation below. If you h | data monitoring                          | g board, study d | ommercial, private foundation, etc.) for esign, manuscript preparation, ess the "ADD" button to add a row. |  |  |  |
| Name of Institut                                                                           | ion/Company                                                     | Grant? Personal N                                               | on-Financial Support?                    | Other? Co        | mments                                                                                                     |  |  |  |
| German Center for Lu                                                                       | ing Research (DZL)                                              | <b>✓ ✓</b>                                                      |                                          |                  |                                                                                                            |  |  |  |
|                                                                                            | l                                                               |                                                                 |                                          |                  |                                                                                                            |  |  |  |
| Section 3.                                                                                 | Relevant financial                                              | activities outside the                                          | submitted                                | work.            |                                                                                                            |  |  |  |
| of compensation<br>clicking the "Add<br>Are there any rel                                  | ) with entities as descri                                       | bed in the instructions.<br>Port relationships that w           | Use one line for<br>ere <b>present d</b> | or each entity;  | elationships (regardless of amount<br>add as many lines as you need by<br>months prior to publication.     |  |  |  |
| Section 4.                                                                                 | Intellectual Proper                                             | ty Patents & Copy                                               | rights                                   |                  |                                                                                                            |  |  |  |
| Do you have any                                                                            | patents, whether plani                                          | ned, pending or issued,                                         | broadly releva                           | nt to the work   | ? Yes 🗸 No                                                                                                 |  |  |  |

Schneider 2



| Section 5. Polationships not sovered above                                                                                                                                                                                           |  |  |  |  |  |  |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--|--|--|--|--|--|
| Relationships not covered above                                                                                                                                                                                                      |  |  |  |  |  |  |
| Are there other relationships or activities that readers could perceive to have influenced, or that give the appearance of potentially influencing, what you wrote in the submitted work?                                            |  |  |  |  |  |  |
| Yes, the following relationships/conditions/circumstances are present (explain below):                                                                                                                                               |  |  |  |  |  |  |
| ✓ No other relationships/conditions/circumstances that present a potential conflict of interest                                                                                                                                      |  |  |  |  |  |  |
| At the time of manuscript acceptance, journals will ask authors to confirm and, if necessary, update their disclosure statements On occasion, journals may ask authors to disclose further information about reported relationships. |  |  |  |  |  |  |
| Section 6. Disclosure Statement                                                                                                                                                                                                      |  |  |  |  |  |  |
| Based on the above disclosures, this form will automatically generate a disclosure statement, which will appear in the box below.                                                                                                    |  |  |  |  |  |  |
| Dr. Schneider reports grants and personal fees from German Center for Lung Research (DZL), during the conduct of the study; .                                                                                                        |  |  |  |  |  |  |

## **Evaluation and Feedback**

Please visit <a href="http://www.icmje.org/cgi-bin/feedback">http://www.icmje.org/cgi-bin/feedback</a> to provide feedback on your experience with completing this form.

Schneider 3